Joachim Widder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7167968/publications.pdf

Version: 2024-02-01

69 papers

3,871 citations

236925 25 h-index 61 g-index

73 all docs 73 docs citations

times ranked

73

4590 citing authors

#	Article	IF	CITATIONS
1	Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and Oncology, 2022, 167, 7-13.	0.6	23
2	Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. Strahlentherapie Und Onkologie, 2022, , 1.	2.0	1
3	Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer. Brachytherapy, 2022, 21, 186-192.	0.5	6
4	Can Generative Adversarial Networks help to overcome the limited data problem in segmentation?. Zeitschrift Fur Medizinische Physik, 2022, 32, 361-368.	1.5	8
5	A novel bone suppression algorithm in intensityâ€based 2D/3D image registration for realâ€time tumor motion monitoring: Development and phantomâ€based validation. Medical Physics, 2022, 49, 5182-5194.	3.0	5
6	Interim analysis of neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial Journal of Clinical Oncology, 2022, 40, e15604-e15604.	1.6	2
7	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
8	Comparing the efficacy of \hat{l}^3 - and electron-irradiation of PBMCs to promote secretion of paracrine, regenerative factors. Molecular Therapy - Methods and Clinical Development, 2021, 21, 14-27.	4.1	2
9	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	2.6	9
10	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiotherapy and Oncology, 2020, 145, 45-48.	0.6	9
11	Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer. Strahlentherapie Und Onkologie, 2020, 196, 983-992.	2.0	7
12	The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray. Cancers, 2020, 12, 563.	3.7	5
13	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
14	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. European Journal of Cancer, 2020, 127, 12-20.	2.8	26
15	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
16	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer $\hat{a} \in \mathbb{C}$ Decision criteria in routine practise. Radiotherapy and Oncology, 2020, 150, 26-29.	0.6	13
17	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.6	24
18	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.6	14

#	Article	IF	Citations
19	Oligometastases. Journal of Thoracic Oncology, 2018, 13, e60.	1.1	1
20	Postoperative radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2018, 194, 23-30.	2.0	10
21	Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. Clinical Oncology, 2018, 30, 17-22.	1.4	6
22	Advances in Breast Radiotherapy: Brachytherapy, Intraoperative Electron Therapy, Protons, and Nodal Irradiation. Breast Care, 2018, 13, 155-156.	1.4	0
23	Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases. Journal of Thoracic Oncology, 2017, 12, 1442-1445.	1.1	71
24	Synchronous or Metachronous Oligometastases. Journal of Thoracic Oncology, 2017, 12, e191-e192.	1.1	5
25	Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters. Oncologist, 2017, 22, 1257-1264.	3.7	29
26	Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 661-669.	0.8	59
27	Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. British Journal of Surgery, 2016, 103, 1055-1062.	0.3	96
28	The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2016, 95, 30-36.	0.8	105
29	Metaâ€enalysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer Science, 2015, 106, 782-782.	3.9	0
30	Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. Journal of Thoracic Oncology, 2015, 10, 826-831.	1.1	85
31	Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?. Radiotherapy and Oncology, 2015, 114, 85-90.	0.6	116
32	An instrument dedicated for modelling of pulmonary radiotherapy. Radiotherapy and Oncology, 2015, 115, 3-8.	0.6	3
33	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology, The, 2015, 16, 630-637.	10.7	1,220
34	A new CT-based method to quantify radiation-induced lung damage in patients. Radiotherapy and Oncology, 2015, 117, 4-8.	0.6	33
35	Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. Radiotherapy and Oncology, 2015, 117, 44-48.	0.6	84
36	Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies. Radiotherapy and Oncology, 2014, 113, 198-203.	0.6	66

#	Article	IF	Citations
37	Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer. Radiation Oncology, 2014, 9, 190.	2.7	8
38	Dose–volume–response analysis in stereotactic radiotherapy for early lung cancer. Radiotherapy and Oncology, 2014, 112, 262-266.	0.6	18
39	The origins of radiotherapy: Discovery of biological effects of X-rays by Freund in 1897, Kienböck's crucial experiments in 1900, and still it is the dose. Radiotherapy and Oncology, 2014, 112, 150-152.	0.6	10
40	Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiotherapy and Oncology, 2013, 107, 267-273.	0.6	408
41	Multi-institutional Quantitative Evaluation and Clinical Validation of Smart Probabilistic Image Contouring Engine (SPICE) Autosegmentation of Target Structures and Normal Tissues on Computer Tomography Images in the Head and Neck, Thorax, Liver, and Male Pelvis Areas. International Journal of Radiation Oncology Biology Physics. 2013, 87, 809-816.	0.8	34
42	Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy?. Radiotherapy and Oncology, 2013, 107, 409-413.	0.6	121
43	PET Imaging of Tumor Hypoxia Using ¹⁸ F-Fluoroazomycin Arabinoside in Stage Ill–IV Non–Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2013, 54, 1175-1180.	5.0	73
44	Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control. International Journal of Radiation Oncology Biology Physics, 2012, 83, e551-e555.	0.8	72
45	18F-FLT-PET for detection of rectal cancer. Radiotherapy and Oncology, 2011, 98, 357-359.	0.6	22
46	Survival and Quality of Life After Stereotactic or 3D-Conformal Radiotherapy for Inoperable Early-Stage Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e291-e297.	0.8	76
47	Preoperative Chemotherapy with Cisplatin and Docetaxel Followed by Surgery and Clip-Oriented Postoperative Chemoradiation in Patients with Localized Gastric or Gastroesophageal Junction Adenocarcinoma: Results from a Phase II Feasibility Study. Annals of Surgical Oncology, 2011, 18, 677-683.	1.5	10
48	18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1059-1063.	6.4	16
49	Quality Assurance of 4D-CT Scan Techniques in Multicenter Phase III Trial of Surgery Versus Stereotactic Radiotherapy (Radiosurgery or Surgery for Operable Early Stage (Stage 1A)) Tj ETQq1 1 0.784314 rg Physics. 2011. 80. 918-927.	gBT/Overl	ock 10 Tf 50
50	Optimizing dose prescription in stereotactic body radiotherapy for lung tumours using Monte Carlo dose calculation. Radiotherapy and Oncology, 2010, 94, 42-46.	0.6	18
51	Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncology, 2009, 4, 1.	2.7	226
52	In Reply to Dr. Xiao et al International Journal of Radiation Oncology Biology Physics, 2009, 75, 318.	0.8	4
53	Radiation dose associated with local control in advanced anal cancer: Retrospective analysis of 129 patients. Radiotherapy and Oncology, 2008, 87, 367-375.	0.6	42
54	Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer. Acta Oncol \tilde{A}^3 gica, 2005, 44, 921-923.	1.8	18

#	Article	IF	CITATIONS
55	Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). British Journal of Cancer, 2005, 92, 1209-1214.	6.4	40
56	The origins of medical evidence: Communication and experimentation. Medicine, Health Care and Philosophy, 2004, 7, 99-104.	1.8	4
57	Impaired Quality of Life in Patients Commencing Radiotherapy for Cancer. Strahlentherapie Und Onkologie, 2004, 180, 78-83.	2.0	25
58	Hyperfractionated accelerated radiochemotherapy (HFA-RCT) with mitomycin C for advanced head and neck cancer. Radiotherapy and Oncology, 2004, 73, 173-177.	0.6	7
59	Basic ideas of medicine. Lancet, The, 2003, 361, 783.	13.7	0
60	Measurement of Quality of Life in Head and Neck Cancer Patients Utilizing the Quality of Life Radiation Therapy Questionnaire. Strahlentherapie Und Onkologie, 2002, 178, 153-158.	2.0	21
61	The concept of disease in palliative medicine. Medicine, Health Care and Philosophy, 2002, 5, 191-197.	1.8	6
62	Quality assurance in preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-run. Radiotherapy and Oncology, 2000, 56, 341-347.	0.6	21
63	The Significance of "Alternative Medicine―for the Philosophy of Medicine. , 2000, , 67-74.		1
64	The fallibility of medical judgment as a consequence of the inexactness of observations. , 1998, 1, 119-124.		2
65	Does medicine need "conceptual frameworks?"A commentary to Lennart Nordenfelt. Medicine, Health Care and Philosophy, 1998, 1, 17-18.	1.8	0
66	Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 803-806.	0.8	46
67	Randomising means, not aims in clinical trials. Lancet, The, 1994, 343, 359.	13.7	4
68	The immunoregulatory influence of transforming growth factor beta in thyroid autoimmunity: TGF \hat{l}^2 inhibits autoreactivity in Graves' disease. Journal of Autoimmunity, 1991, 4, 689-701.	6.5	18
69	The predictive value of behavioural risk factors for sudden infant death. Early Human Development, 1988, 18, 101-109.	1.8	31